Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-7/IL-7R Expression in RA Treated with DMARDs and/or Cimzia
NCT02451748Phase 4Completed
- Sponsor
- University of Illinois Chicago
- Start
- Aug 2015
- Primary completion
- Sep 2017
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by University of Illinois Chicago. Started Aug 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02451748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451748.